Cizzle Biotechnology launches its new corporate website

Cizzle Biotechnology Holdings

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer of early cancer tests, has announce that it has launched its new corporate website, which can be viewed at: https://cizzlebiotechnology.com

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

“I am delighted to announce that our new website is now live for all stakeholders including shareholders, investors and customers, to access a wide range of information and latest news on the Company’s status and products. This is an exciting time for Cizzle Biotechnology as we continue to finalise our near term regulatory and launch plans in the USA as part of our global strategy to bring the non-invasive, cost effective, CIZ1B Biomarker test for early-stage lung cancer to market.  The new website is designed to provide a user-friendly interface for all stakeholders and we look forward to adding new content as part of an enhanced communication strategy to support the Company’s growth.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Cizzle Biotechnology US Rollout Begins as Lung Cancer Test Moves from Lab to Clinic (Video)

    Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand.

    Cizzle Biotechnology expands North American rollout of CIZ1B lung cancer test

    Cizzle Biotechnology has confirmed further progress in the US launch of its CIZ1B biomarker test through exclusive partner Cizzle Bio Inc, which is completing validation with Omni Health Diagnostics.

    Cizzle Biotechnology to launch CIZ1B cancer test across USA

    Cizzle Biotechnology has announced that its North American partner, Cizzle Bio Inc, has signed an agreement with a multi-site accredited laboratory group to roll out the CIZ1B biomarker test for early lung cancer detection across the USA.

    Cizzle Biotechnology raises £150k to support cancer test rollout

    Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe.

    Cizzle Bio expands into Caribbean with first contract, secures early royalties

    Cizzle Biotechnology announces significant strides in early lung cancer detection through its partner's first Caribbean contract, boosting its biomarker test rollout.

    Cizzle Biotechnology launches its new corporate website

    Cizzle Biotechnology Holdings plc has launched a new corporate website, enhancing access to vital information about its early cancer tests and growth strategy.

      Search

      Search